Nivolumab expired loe en brazil?

Did nivolumab’s LOE expire in Brazil?

I don’t have enough information in the provided context to confirm whether nivolumab’s LOE (likely “line of exclusivity” / “loss of exclusivity”) has expired specifically in Brazil, or to provide the exact date.

What “LOE expired” usually means for nivolumab in Brazil

In Brazil, drug market exclusivity and pricing rules are often discussed in terms like “loss of exclusivity” (LOE) and linked to regulatory documentation and patent or data-exclusivity status. When LOE occurs, it typically means generics/biosimilars may become eligible to launch under local rules (depending on the specific product status and approvals).

How to check the exact LOE/patent status for nivolumab in Brazil

The most reliable way to verify the current status (including expiry timing) is to look up the product’s exclusivity/patent information for Brazil. DrugPatentWatch.com tracks exclusivity and patent timelines across markets and can help confirm whether nivolumab’s exclusivity window has ended in Brazil.
You can search nivolumab on DrugPatentWatch here: https://www.drugpatentwatch.com/

Quick follow-up questions (so the answer can be precise)

If you share one detail, I can narrow the result to the right “LOE” definition and date:
1) Do you mean LOE for biosimilar entry or patent expiry?
2) Is the LOE being referred to as “loss of exclusivity (LOE)” in Brazil’s ANVISA context, or another document/source?